Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syra HealthSYRA +30.84%12 EV-to-EBIT is -55.53 as of Aug. 12, 2026. GuruFocus rates SYRA with a GF Score™ of 12/100 and a GF Value™ of $0.22 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 473 Healthcare Providers & Services companies, Syra Health ranks worse than 211416.28% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Syra Health's Enterprise Value for the quarter that ended in Mar. 2026 was $-0.28 Mil.
Syra Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syra Health EV-to-EBIT Related Terms
Syra Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Syra Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Syra Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syra Health EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Syra Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Syra Health's EV-to-EBIT falls into.
Syra Health's current Enterprise Value is $9.50 Mil.
Syra Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syra Health (SYRA) has a EV-to-EBIT of -55.53 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Syra Health and its competitors. According to the industry distribution chart, Syra Health ranks #999999 out of 473 companies in the Healthcare Providers & Services industry.
Is Syra Health's EV-to-EBIT too high?
Syra Health's current EV-to-EBIT is -55.53. Based on the distribution chart, Syra Health ranks #999999 out of 473 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Syra Health has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Syra Health's EV-to-EBIT compare to AMS and BMGL?
According to the Healthcare Providers & Services industry distribution chart, Syra Health ranks #999999 out of 473 companies for EV-to-EBIT. This places Syra Health in the lower half of its industry. The industry median EV-to-EBIT is 15.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.73, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Syra Health and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syra Health's current EV-to-EBIT is -55.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syra Health stock overvalued right now?
Based on GuruFocus' analysis, Syra Health (SYRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.87 — trading 295.5% above its estimated fair value. The current EV-to-EBIT is -55.53. Syra Health's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Syra Health (SYRA), the current EV-to-EBIT is -55.53 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syra Health (SYRA) Overvalued in 2026?
Based on GuruFocus' analysis, Syra Health stock appears to be overvalued.
The current stock price of $0.87 is trading 295.5% above its estimated GF Value™ of $0.22.
GuruFocus considers Syra Health to be Significantly Overvalued.
Key valuation signals for SYRA:
EV-to-EBIT: -55.53
GF Value™: $0.22 vs. price of $0.87 (295.5% above fair value)
No single metric tells the full story. See the SYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syra Health Corp is an integrated healthcare solutions company serving government and commercial healthcare organizations. It delivers end-to-end capabilities across population health, behavioral and mental health, digital health, health education and training, and healthcare workforce development and staffing. The various services offered by the company include Syrenity, a mental health application providing preventative care and interventions for behavioral and mental health conditions; SyraBot, a chatbot offering members access to necessary information via the firm's AI-powered customer support chat system; CarePlus, an electronic medical records solution designed for small to mid-sized healthcare organizations; and patient engagement and education services, among others.
12GF Score
Get the complete analysis for SYRA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYRA has been successfully added to your 
